<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-POT-2303</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-2459</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Пептиды врожденного иммунитета как потенциальные противоопухолевые агенты: плюсы и минусы</article-title><trans-title-group xml:lang="en"><trans-title>Peptides of the innate immunity as potential anticancer agents: pros and cons</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Чернов Александр Николаевич – научный сотрудник отдела общей патологии и патологической физиологии.</p><p>197376, Санкт-Петербург, ул. Акад. Павлова, 12. Тел.: 8 (960) 270-43-97</p></bio><bio xml:lang="en"><p>Chernov Alexander N. - Research Associate, Department of General Pathology and Pathological Physiology.</p><p>197376, St. Petersburg, Acad. Pavlov str., 12. Phone: 7 (960) 270-43-97</p></bio><email xlink:type="simple">al.chernov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Орлов</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Orlov</surname><given-names>D. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, доцент, заведующий лабораторией иммунопатофизиологии отдела общей патологии и патологической физиологии.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>PhD (Medicine), Associate Professor, Head, Laboratory of Immunopathophysiology, Department of General Pathology and Pathological Physiology.</p><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шамова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shamova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор биологических наук, доцент, член-корр. РАН, заведующая отделом общей патологии и патологической физиологии, заместитель директора по научной работе</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>PhD, MD (Biology), Associate Professor, Corresponding Member, Russian Academy of Sciences, Head, Department of General Pathology and Pathological Physiology, Deputy Director for Research IEM; Professor, Department of Biochemistry, Faculty of Biology, St. Petersburg SU.</p><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Институт экспериментальной медицины</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Experimental Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ Институт экспериментальной медицины; ФГБОУ ВО Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Experimental Medicine; St. Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>21</day><month>12</month><year>2021</year></pub-date><volume>23</volume><issue>6</issue><fpage>1285</fpage><lpage>1306</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Чернов А.Н., Орлов Д.С., Шамова О.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Чернов А.Н., Орлов Д.С., Шамова О.В.</copyright-holder><copyright-holder xml:lang="en">Chernov A.N., Orlov D.S., Shamova O.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2459">https://www.mimmun.ru/mimmun/article/view/2459</self-uri><abstract><p>Онкологические заболевания представляют серьезную социально-экономическую проблему. Основным подходом к терапии опухолей является их хирургическая резекция, часто дополняемая лучевой и химиотерапией. Эффективность такого комплексного лечения во многих случаях остается невысокой. В связи с этим возникает острая необходимость поиска новых соединений, обладающих селективной цитотоксической активностью в отношении опухолевых клеток и не повреждающих нормальные ткани организма. В обзоре рассматриваются механизмы противоопухолевого действия катионных антимикробных пептидов (АМП) семейства кателицидинов – α-спирального кателицидина человека (LL-37) и пептида с конформацией β-шпильки – протегрина-1 (PG-1) на клетки рака легкого, молочной, поджелудочной, предстательной желез, меланомы, плоскоклеточного рака кожи, полости рта, желудка, яичников, колоректального рака, лейкозов, лимфом, глиом и нейробластом. Обсуждается возможность противоопухолевого и противоположного – проонкогенного действия пептидов и взаимосвязь этих эффектов c иммуномодулирующей активностью АМП на опухоль-ассоциированные макрофаги, естественные киллерные клетки и T-лимфоциты. Приводятся возможные механизмы селективного действия LL-37 и PG-1 на опухолевые клетки, включающее взаимодействие LL-37 с G-белок-связанными рецепторами: N-формилпептида-2 (FPR2), CXC хемокина-2 (CXCR2), Mas-ассоциированным с геном X (MrgX2), пуринергическим (P2Y11), эпидермального (EGFR/ErbB1, ERBb2), инсулино-подобного (IGF1R) факторов роста, лиганд-управляемых ионных каналов (LGIC) и Toll-подобными (TLR) рецепторами, экспрессия которых значительно изменяется в разных типах опухолей по сравнению с нормой. Однако при этом особенно важно учитывать, что терапевтические эффекты LL-37 и его производных могут использоваться только для конкретных типов опухолей. Механизмы действия PG-1 на опухолевые клетки остаются еще плохо изученными, хотя имеющиеся данные свидетельствуют, что протегрин проявляет более однонаправленное действие – повреждает мембраны. Протегрин-1 и LL-37 могут синергически усиливать противоопухолевые эффекты химиопрепаратов и оказывают более выраженное действие на опухолевые, чем на нормальные клетки. Природные АМП представляются перспективными кандидатами на роль новых противоопухолевых средств, которые проявляют активность и в отношении злокачественных метастазирующих, рецидивирующих опухолей с множественной лекарственной устойчивостью. С другой стороны, такие пептиды, как LL-37, проявляют в некоторых случаях свойства, которые могут рас- сматриваться как проонкогенные, что указывает на необходимость дальнейшего детального изучения молекулярных механизмов их действия на опухолевые клетки.</p></abstract><trans-abstract xml:lang="en"><p>Surgical resection was the main approach to cancer therapy, often supplemented by radiation and chemotherapy. The effectiveness of such complex treatment in many cases remains low. In this regard, there is an urgent need to search for new compounds that have selective cytotoxic activity against tumor cells and do not damage normal tissues of the organism. The review discusses mechanisms of antitumor action of cationic antimicrobial peptides (AMPs) of the cathelicidin family - human α-helical cathelicidin (LL-37), and a peptide with β-hairpin conformation – protegrin-1 (PG-1) on lung, breast, pancreas, prostate, squamous skin cancer cells, oral cancer, stomach, ovarian, colorectal cancer, melanoma, leukemia, lymphoma, glioma and neuroblastoma cells. An opportunity of antitumor and pro-oncogenic actions of the peptides and an interplay of these effects with mmunomodulatory action of AMPs on tumor-associated macrophages, natural killer cells and T-lymphocytes is discussed. Possible mechanisms of LL-37 and PG-1 selective action upon tumor cells are presented, including the interaction of LL-37 with G-protein-coupled receptors: the N formylpeptide-2 receptor (FPR2), CXC chemokine-2 (CXCR2), Mas-related gene X2 (MrgX2), purinergic (P2Y11), epidermal (EGFR/ErbB1, ERBb2), insulin-like (IGF1R) growth factors, ligand-gated ion channels (LGIC) and Tolllike (TLR) receptors, with expression varying significantly in different types of tumors, as compared to normal tissues. An increase in the level of LL-37 secretion and expression of its CAMP gene are associated with progression of lung adenocarcinoma, breast, pancreas, and prostate cancer, ovarian cancer, melanoma, and squamous cell carcinoma of the skin. In contrast, CAMP expression and LL-37 secretion are significantly reduced in gastric cancer cells, oral squamous cell cancer, colorectal cancer, leukemia, lymphomas, gliomas, and SH-SY5Y neuroblastoma. Therefore, therapeutic effects of LL-37 can only be used for specific types of tumors. The mechanisms of action of PG-1 on tumor cells are still poorly understood, although the available data indicate that protegrin exhibits a more unidirectional effect, i.e., it damages cell membranes. Protegrin-1 and LL-37 can synergistically enhance the antitumor effects of chemotherapy drugs and have a more pronounced effect on tumor cells, than upon normal cells. Natural AMPs appear to be promising candidates for the role of new antitumor agents, which are also active against malignant metastatic, recurrent multidrug-resistant tumors. On the other hand, peptides such as LL-37, in some cases, exhibit properties that can be considered pro-oncogenic, which indicates a need for further detailed studies on the molecular mechanisms of their action on tumor cells.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>пептиды семейства кателицидинов</kwd><kwd>LL-37</kwd><kwd>протегрин-1</kwd><kwd>опухоль</kwd><kwd>механизмы противоопухолевого действия</kwd><kwd>механизмы проонкогенного действия</kwd><kwd>врожденный иммунитет</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cathelicidin family</kwd><kwd>LL-37</kwd><kwd>protegrin-1</kwd><kwd>tumor</kwd><kwd>antitumor mechanisms</kwd><kwd>protooncogenic effects</kwd><kwd>innate immunity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Абатуров А.Е., Никулина А.А. Развитие иммунного ответа при стафилококковой пневмонии (часть 4) // Здоровье ребенка, 2017. № 12. С. 648-656.</mixed-citation><mixed-citation xml:lang="en">Abaturov A.E., Nikulina A.A. Development of the immune response in staphylococcal pneumonia (part 4). Zdorovye rebenka = Child Health, 2017, no. 12, pp. 648-656. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Баландин С.В., Емельянова А.А., Калашникова М.Б., Кокряков В.Н., Шамова О.В., Овчинникова Т.В. Молекулярные механизмы противоопухолевого действия природных антимикробных пептидов // Биоорганическая химия, 2016. Т. 42, № 6. С. 633-648.</mixed-citation><mixed-citation xml:lang="en">Balandin S.V., Emelyanova A.A., Kalashnikova M.B., Kokryakov V.N., Shamova O.V., Ovchinnikova T.V. Molecular mechanisms of the antitumor action of natural antimicrobial peptides. Bioorganicheskaya khimiya = Bioorganic Chemistry, 2016, Vol. 42, no. 6, pp. 633-648. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Жаркова М.С. Сочетанное действие белков и пептидов системы врожденного иммунитета и соединений различной химической природы в реализации их антибиотических свойств: автореф. … канд. биол. наук. СПб.: Институт экспериментальной медицины, 2016. 23 с.</mixed-citation><mixed-citation xml:lang="en">Zharkova M.S. The combined effect of proteins and peptides of the innate immunity system and compounds of various chemical nature in the implementation of their antibiotic properties. Abstract of PhD thesis. St. Petersburg: Institute of Experimental Medicine, 2016. 23 p.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Жаркова М.С., Артамонов А.Ю., Гринчук Т.М., Буцкина Е.А., Пазина Т.Ю., Орлов Д.С., Шамова О.В. Пептиды системы врожденного иммунитета модулируют цитотоксическое действие противоопухолевых антибиотиков // Российский иммунологический журнал, 2016. Т. 10, № 2. C. 548-550.</mixed-citation><mixed-citation xml:lang="en">Zharkova M.S., Artamonov A.Yu., Grinchuk T.M., Butskina E.A., Pazina T.Yu., Orlov D.S., Shamova O.V. Peptides of the innate immune system modulate the cytotoxic effect of antitumor antibiotics. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2016, Vol. 10, no. 2, pp. 548-550. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шамова О.В., Орлов Д.С., Пазина Т.Ю., Ямщикова Е.В., Орлов С.Б., Жаркова М.С., Гринчук Т.М., Арцыбашева И.В., Юхнев В.А., Кокряков В.Н. Изучение молекулярно-клеточных основ цитотоксического действия антимикробных пептидов на опухолевые клетки // Фундаментальные исследования, 2012. № 5, Ч. 1. С. 207-212.</mixed-citation><mixed-citation xml:lang="en">Shamova O.V., Orlov D.S., Pazina T.Yu., Yamshchikova E.V., Orlov S.B., Zharkova M.S., Grinchuk T.M., Artsybasheva I.V., Yukhnev V.A., Kokryakov V.N. Study of the molecular and cellular bases of the cytotoxic effect of antimicrobial peptides on tumor cells. Fundamentalnye issledovaniya = Fundamental Research, 2012, no. 5, Pt 1, pp. 207-212. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шамова О.В., Сакута Г.А., Орлов Д.С., Зенин В.В., Штейн Г.И., Колодкин Н.И., Афонина И.Н., Кокряков В.Н. Действие атимикробных пептидов из нейтрофильных гранулоцитов на опухолевые и нормальные клетки в культуре // Цитология, 2007. Т. 49, № 12. С. 1000-1010.</mixed-citation><mixed-citation xml:lang="en">Shamova O.V., Sakuta G.A., Orlov D.S., Zenin V.V., Stein G.I., Kolodkin N.I., Afonina I.N., Kokryakov V.N. The effect of antimicrobial peptides from neutrophilic granulocytes on tumor and normal cells in culture. Tsitologiya = Cytologiya, 2007, Vol. 49, no. 12, pp. 1000-1010. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., Kiessling R., Jörnvall H., Wigzell H., Gudmundsson G.H. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood, 2000, Vol. 96, no. 9, pp. 3086-3093.</mixed-citation><mixed-citation xml:lang="en">Agerberth B., Charo J., Werr J., Olsson B., Idali F., Lindbom L., Kiessling R., Jörnvall H., Wigzell H., Gudmundsson G.H. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood, 2000, Vol. 96, no. 9, pp. 3086-3093.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alzahrani S., Lina T.T., Gonzalez J., Pinchuk I.V., Beswick E.J., Reyes V.E. Effect of Helicobacter pylori on gastric epithelial cells. World J. Gastroenterol., 2014, Vol. 20, pp. 12767-12780.</mixed-citation><mixed-citation xml:lang="en">Alzahrani S., Lina T.T., Gonzalez J., Pinchuk I.V., Beswick E.J., Reyes V.E. Effect of Helicobacter pylori on gastric epithelial cells. World J. Gastroenterol., 2014, Vol. 20, pp. 12767-12780.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">An L.L., Yang Y.H., Ma X.T., Lin Y.M., Li G., Song Y.H., Wu K.F. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk. Res., 2005, Vol. 29, no. 5, pp. 535-543.</mixed-citation><mixed-citation xml:lang="en">An L.L., Yang Y.H., Ma X.T., Lin Y.M., Li G., Song Y.H., Wu K.F. LL-37 enhances adaptive antitumor immune response in a murine model when genetically fused with M-CSFR (J6-1) DNA vaccine. Leuk. Res., 2005, Vol. 29, no. 5, pp. 535-543.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Armogida S.A., Yannaras N.M., Melton A.L. Srivastava M.D. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc., 2004, Vol. 25, no. 5, pp. 297-304.</mixed-citation><mixed-citation xml:lang="en">Armogida S.A., Yannaras N.M., Melton A.L. Srivastava M.D. Identification and quantification of innate immune system mediators in human breast milk. Allergy Asthma Proc., 2004, Vol. 25, no. 5, pp. 297-304.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Arnoult D., Gaume B., Karbowski M., Sharpe J.C., Cecconi F., Youle R.J. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO, 2003, Vol. 22, no. 17, pp. 4385-4399.</mixed-citation><mixed-citation xml:lang="en">Arnoult D., Gaume B., Karbowski M., Sharpe J.C., Cecconi F., Youle R.J. Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO, 2003, Vol. 22, no. 17, pp. 4385-4399.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Bals R., Wang X., Zasloff M., Wilson J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA., 1998, Vol. 95, no. 16, pp. 9541-9546.</mixed-citation><mixed-citation xml:lang="en">Bals R., Wang X., Zasloff M., Wilson J.M. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc. Natl Acad. Sci. USA., 1998, Vol. 95, no. 16, pp. 9541-9546.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett., 2001, Vol. 490, no. 3, pp. 117-122.</mixed-citation><mixed-citation xml:lang="en">Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett., 2001, Vol. 490, no. 3, pp. 117-122.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bruns H., Büttner M., Fabri M., Mougiakakos D., Bittenbring J.T., Hoffmann M.H., Beier F., Pasemann S., Jitschin R., Hofmann A.D., Neumann F., Daniel C., Maurberger A., Kempkes B., Amann K., Mackensen A., Gerbitz A. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci. Transl. Med., 2015, Vol. 7, no. 282, 282ra47. doi: 10.1126/scitranslmed.aaa3230.</mixed-citation><mixed-citation xml:lang="en">Bruns H., Büttner M., Fabri M., Mougiakakos D., Bittenbring J.T., Hoffmann M.H., Beier F., Pasemann S., Jitschin R., Hofmann A.D., Neumann F., Daniel C., Maurberger A., Kempkes B., Amann K., Mackensen A., Gerbitz A. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci. Transl. Med., 2015, Vol. 7, no. 282, 282ra47. doi: 10.1126/scitranslmed.aaa3230.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Büchau A.S., Morizane S., Trowbridge J., Schauber J., Kotol P., Bui J.D., Gallo R.L. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol., 2010, Vol. 184, no. 1, pp. 369-378.</mixed-citation><mixed-citation xml:lang="en">Büchau A.S., Morizane S., Trowbridge J., Schauber J., Kotol P., Bui J.D., Gallo R.L. The host defense peptide cathelicidin is required for NK cell-mediated suppression of tumor growth. J. Immunol., 2010, Vol. 184, no. 1, pp. 369-378.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., Schleker T., Perna D., Tronnersjo S., Murga M., Fernandez Capetillo O., Barbacid M., Larsson L.G., Amati B. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol., 2010, Vol. 12, no. 1, pp. 54-59.</mixed-citation><mixed-citation xml:lang="en">Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., Schleker T., Perna D., Tronnersjo S., Murga M., Fernandez Capetillo O., Barbacid M., Larsson L.G., Amati B. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol., 2010, Vol. 12, no. 1, pp. 54-59.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Can G., Akpinar B., Baran Y., Zhivotovsky B., Olsson M. 5-Fluorouracil signaling through a calciumcalmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013, Vol. 32, no. 38, pp. 4529-4538.</mixed-citation><mixed-citation xml:lang="en">Can G., Akpinar B., Baran Y., Zhivotovsky B., Olsson M. 5-Fluorouracil signaling through a calciumcalmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene, 2013, Vol. 32, no. 38, pp. 4529-4538.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Carmona F.J., Montemurro F., Kannan S., Rossi V., Verma C., Baselga J., Scaltriti M. AKT signaling in ERBB2-amplified breast cancer. Pharmacol. Ther., 2016, Vol. 158, pp. 63-70.</mixed-citation><mixed-citation xml:lang="en">Carmona F.J., Montemurro F., Kannan S., Rossi V., Verma C., Baselga J., Scaltriti M. AKT signaling in ERBB2-amplified breast cancer. Pharmacol. Ther., 2016, Vol. 158, pp. 63-70.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Chen P.M., Yen M.L., Liu K.J., Sytwu H.K., Yen B.L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J. Biomed. Sci., 2011, Vol. 18, no. 1, 49. doi: 10.1186/1423-0127-18-49.</mixed-citation><mixed-citation xml:lang="en">Chen P.M., Yen M.L., Liu K.J., Sytwu H.K., Yen B.L. Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J. Biomed. Sci., 2011, Vol. 18, no. 1, 49. doi: 10.1186/1423-0127-18-49.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X., Qi G., Qin M., Zou Y., Zhong K., Tang Y., Guo Y., Jiang X., Liang L., Zou X. DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene (CAMP) promoter activity. Oncotarget, 2017, Vol. 8, no. 17, pp. 27943-27952.</mixed-citation><mixed-citation xml:lang="en">Chen X., Qi G., Qin M., Zou Y., Zhong K., Tang Y., Guo Y., Jiang X., Liang L., Zou X. DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene (CAMP) promoter activity. Oncotarget, 2017, Vol. 8, no. 17, pp. 27943-27952.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X., Zou X., Qi G., Tang Y., Guo Y., Si J., Liang L. Roles and mechanisms of human cathelicidin LL-37 in сancer. Cell. Physiol. Biochem., 2018, Vol. 47, no. 3, pp. 1060-1073.</mixed-citation><mixed-citation xml:lang="en">Chen X., Zou X., Qi G., Tang Y., Guo Y., Si J., Liang L. Roles and mechanisms of human cathelicidin LL-37 in сancer. Cell. Physiol. Biochem., 2018, Vol. 47, no. 3, pp. 1060-1073.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng M., Ho S., Yoo J.H., Tran D. H.-Y., Bakirtzi K., Su B., Tran D. H.-N., Kubota Y., Ichikawa R., Koon H.W. Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clin. Exp. Gastroenterol., 2014, Vol. 8, pp. 13-29.</mixed-citation><mixed-citation xml:lang="en">Cheng M., Ho S., Yoo J.H., Tran D. H.-Y., Bakirtzi K., Su B., Tran D. H.-N., Kubota Y., Ichikawa R., Koon H.W. Cathelicidin suppresses colon cancer development by inhibition of cancer associated fibroblasts. Clin. Exp. Gastroenterol., 2014, Vol. 8, pp. 13-29.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Choi K.Y., Napper S., Mookherjee N. Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin32-induced inflammation. Immunology, 2014, Vol. 143, no.1, pp. 68-80.</mixed-citation><mixed-citation xml:lang="en">Choi K.Y., Napper S., Mookherjee N. Human cathelicidin LL-37 and its derivative IG-19 regulate interleukin32-induced inflammation. Immunology, 2014, Vol. 143, no.1, pp. 68-80.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang C.M., Monie A., Wu A., Mao C-P., Hung C-F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther., 2009, Vol. 20, no. 4, pp. 303-313.</mixed-citation><mixed-citation xml:lang="en">Chuang C.M., Monie A., Wu A., Mao C-P., Hung C-F. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum. Gene Ther., 2009, Vol. 20, no. 4, pp. 303-313.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Coffelt S.B., Waterman R.S., Florez L., Höner zu Bentrup K., Zwezdaryk K.J., Tomchuck S.L., LaMarca H.L., Danka E.S., Morris C.A., Scandurro A.B. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer, 2008, Vol. 122, no. 5, pp. 1030-1039.</mixed-citation><mixed-citation xml:lang="en">Coffelt S.B., Waterman R.S., Florez L., Höner zu Bentrup K., Zwezdaryk K.J., Tomchuck S.L., LaMarca H.L., Danka E.S., Morris C.A., Scandurro A.B. Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int. J. Cancer, 2008, Vol. 122, no. 5, pp. 1030-1039.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Coffelt S.B., Marini F.C., Watson K., Zwezdaryk K.J., Dembinski J.L., LaMarca H.L., Tomchuck S.L., Honer zu Bentrup K., Danka E.S., Henkle S.L., Scandurro A.B. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl Acad. Sci. USA, 2009, Vol. 106, no. 10, pp. 3806-3811.</mixed-citation><mixed-citation xml:lang="en">Coffelt S.B., Marini F.C., Watson K., Zwezdaryk K.J., Dembinski J.L., LaMarca H.L., Tomchuck S.L., Honer zu Bentrup K., Danka E.S., Henkle S.L., Scandurro A.B. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl Acad. Sci. USA, 2009, Vol. 106, no. 10, pp. 3806-3811.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Colle J.-H., Périchon B., Garcia A. Antitumor and antibacterial properties of virally encoded cationic sequences. Biologics, 2019, Vol. 13, pp. 117-126.</mixed-citation><mixed-citation xml:lang="en">Colle J.-H., Périchon B., Garcia A. Antitumor and antibacterial properties of virally encoded cationic sequences. Biologics, 2019, Vol. 13, pp. 117-126.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Dennison S.R., Whittaker M., Harris F., Phoenix D.A. Anticancer alpha-helical peptides and structure/ function relationships underpinning their interactions with tumour cell membranes. Curr. Protein Pept. Sci., 2006, Vol. 7, no. 6, pp. 487-499.</mixed-citation><mixed-citation xml:lang="en">Dennison S.R., Whittaker M., Harris F., Phoenix D.A. Anticancer alpha-helical peptides and structure/ function relationships underpinning their interactions with tumour cell membranes. Curr. Protein Pept. Sci., 2006, Vol. 7, no. 6, pp. 487-499.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Deslouches B., Di P.Y. Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget, 2017, Vol. 8, no. 28, pp. 46635-46651.</mixed-citation><mixed-citation xml:lang="en">Deslouches B., Di P.Y. Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget, 2017, Vol. 8, no. 28, pp. 46635-46651.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">di Virgilio F., Falzoni S., Giuliani A.L., Adinolfi E. P2 receptors in cancer progression and metastatic spreading. Curr. Opin. Pharmacol., 2016, Vol. 29, pp. 17-25.</mixed-citation><mixed-citation xml:lang="en">di Virgilio F., Falzoni S., Giuliani A.L., Adinolfi E. P2 receptors in cancer progression and metastatic spreading. Curr. Opin. Pharmacol., 2016, Vol. 29, pp. 17-25.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Do N., Weindl G., Grohmann L., Salwiczek M., Koksch B., Korting H.C., Schäfer-Korting M. Cationic membrane-active peptides – anticancer and antifungal activity as well as penetration into human skin. Exp. Dermatol., 2014, Vol. 23, no. 5, pp. 326-331.</mixed-citation><mixed-citation xml:lang="en">Do N., Weindl G., Grohmann L., Salwiczek M., Koksch B., Korting H.C., Schäfer-Korting M. Cationic membrane-active peptides – anticancer and antifungal activity as well as penetration into human skin. Exp. Dermatol., 2014, Vol. 23, no. 5, pp. 326-331.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Dobrzyńska I., Szachowicz-Petelska B., Sulkowski S., Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem., 2005, Vol. 276, no. 1-2, pp. 113-119.</mixed-citation><mixed-citation xml:lang="en">Dobrzyńska I., Szachowicz-Petelska B., Sulkowski S., Figaszewski Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells. Mol. Cell. Biochem., 2005, Vol. 276, no. 1-2, pp. 113-119.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Drin G., Cottin S., Blanc E., Rees A.R., Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem., 2003, Vol. 278, no. 33, pp. 31192-31201.</mixed-citation><mixed-citation xml:lang="en">Drin G., Cottin S., Blanc E., Rees A.R., Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem., 2003, Vol. 278, no. 33, pp. 31192-31201.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation – potential for therapeutics and diagnostics. Nat. Rev. Drug Discov., 2005, Vol. 4, no. 6, pp. 477-488.</mixed-citation><mixed-citation xml:lang="en">Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation – potential for therapeutics and diagnostics. Nat. Rev. Drug Discov., 2005, Vol. 4, no. 6, pp. 477-488.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Fan R., Tong A., Li X., Gao X., Mei L., Zhou L., Zhang X., You C., Guo G. Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Intern. J. Nanomedicine, 2015, Vol. 10, pp. 7291-7305.</mixed-citation><mixed-citation xml:lang="en">Fan R., Tong A., Li X., Gao X., Mei L., Zhou L., Zhang X., You C., Guo G. Enhanced antitumor effects by docetaxel/LL37-loaded thermosensitive hydrogel nanoparticles in peritoneal carcinomatosis of colorectal cancer. Intern. J. Nanomedicine, 2015, Vol. 10, pp. 7291-7305.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Farabaugh S.M., Chan B.T., Cui X., Dearth R.K., Lee A.V. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer. Cell Commun. Signal., 2016, Vol. 14, 25. doi: 10.1186/s12964-016-0148-8.</mixed-citation><mixed-citation xml:lang="en">Farabaugh S.M., Chan B.T., Cui X., Dearth R.K., Lee A.V. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer. Cell Commun. Signal., 2016, Vol. 14, 25. doi: 10.1186/s12964-016-0148-8.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol., 2006, Vol. 176, no. 7, pp. 3877-3883.</mixed-citation><mixed-citation xml:lang="en">Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol., 2006, Vol. 176, no. 7, pp. 3877-3883.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Findlay E.G., Currie A.J., Zhang A., Ovciarikova J., Young L., Stevens H., McHugh BJ., Canel M., Gray M., Milling S.W.F., Campbell J.D.M., Savill J., Serrels A., Davidson D.J. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology, 2019, Vol. 8, no. 8, 1608106. doi: 10.1080/2162402X.2019.1608106.</mixed-citation><mixed-citation xml:lang="en">Findlay E.G., Currie A.J., Zhang A., Ovciarikova J., Young L., Stevens H., McHugh BJ., Canel M., Gray M., Milling S.W.F., Campbell J.D.M., Savill J., Serrels A., Davidson D.J. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology, 2019, Vol. 8, no. 8, 1608106. doi: 10.1080/2162402X.2019.1608106.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Frohm M., Agerberth B., Ahangari G., Stâhle-Bäckdahl M., Lidén S., Wigzell H., Gudmundsson G.H. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem., 1997, no. 24, Vol. 272, pp. 15258-15263.</mixed-citation><mixed-citation xml:lang="en">Frohm M., Agerberth B., Ahangari G., Stâhle-Bäckdahl M., Lidén S., Wigzell H., Gudmundsson G.H. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J. Biol. Chem., 1997, no. 24, Vol. 272, pp. 15258-15263.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Gambade A., Zreika S., Guéguinou M., Chourpa I., Fromont G., Bouchet AM., Burlaud-Gaillard J., PotierCartereau M., Roger S., Aucagne V., Chevalier S., Vandier C., Goupille C., Weber G. Activation of TRPV2 and channels by the LL-37 enantiomers stimulates calcium entry and migration of cancer cells. Oncotarget, 2016, Vol. 7, no. 17, pp. 23785-23800.</mixed-citation><mixed-citation xml:lang="en">Gambade A., Zreika S., Guéguinou M., Chourpa I., Fromont G., Bouchet AM., Burlaud-Gaillard J., PotierCartereau M., Roger S., Aucagne V., Chevalier S., Vandier C., Goupille C., Weber G. Activation of TRPV2 and channels by the LL-37 enantiomers stimulates calcium entry and migration of cancer cells. Oncotarget, 2016, Vol. 7, no. 17, pp. 23785-23800.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Gao P., Zhao H., You J., Jing F., Hu Y. Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer Invest., 2014, Vol. 32, pp. 518-525.</mixed-citation><mixed-citation xml:lang="en">Gao P., Zhao H., You J., Jing F., Hu Y. Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis. Cancer Invest., 2014, Vol. 32, pp. 518-525.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Girnita A., Zheng H., Grönberg A., Girnita L., Ståhle M. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene, 2012, Vol. 31, pp. 352-365.</mixed-citation><mixed-citation xml:lang="en">Girnita A., Zheng H., Grönberg A., Girnita L., Ståhle M. Identification of the cathelicidin peptide LL-37 as agonist for the type I insulin-like growth factor receptor. Oncogene, 2012, Vol. 31, pp. 352-365.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J., 2005, Vol. 19, no. 9, pp. 1067-1077.</mixed-citation><mixed-citation xml:lang="en">Gombart A.F., Borregaard N., Koeffler H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. FASEB J., 2005, Vol. 19, no. 9, pp. 1067-1077.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta K., Kotian A., Subramanian H., Daniell H., Ali H. Activation of human mast cells by retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties. Oncotarget, 2015, Vol. 6, no. 30, pp. 28573-28587.</mixed-citation><mixed-citation xml:lang="en">Gupta K., Kotian A., Subramanian H., Daniell H., Ali H. Activation of human mast cells by retrocyclin and protegrin highlight their immunomodulatory and antimicrobial properties. Oncotarget, 2015, Vol. 6, no. 30, pp. 28573-28587.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Hase K., Murakami M., Iimura M., Cole SP., Horibe Y., Ohtake T., Obonyo M., Gallo R.L., Eckmann L., Kagnoff M.F. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology, 2003, Vol. 125, no. 6, pp. 1613-1625.</mixed-citation><mixed-citation xml:lang="en">Hase K., Murakami M., Iimura M., Cole SP., Horibe Y., Ohtake T., Obonyo M., Gallo R.L., Eckmann L., Kagnoff M.F. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori. Gastroenterology, 2003, Vol. 125, no. 6, pp. 1613-1625.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Heilborn J.D., Nilsson M.F., Jimenez C.I., Sandstedt B., Borregaard N., Tham E., Sørensen O.E., Weber G., Ståhle M. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int. J. Cancer., 2005, Vol. 114, no. 5, pp. 713-719.</mixed-citation><mixed-citation xml:lang="en">Heilborn J.D., Nilsson M.F., Jimenez C.I., Sandstedt B., Borregaard N., Tham E., Sørensen O.E., Weber G., Ståhle M. Antimicrobial protein hCAP18/LL-37 is highly expressed in breast cancer and is a putative growth factor for epithelial cells. Int. J. Cancer., 2005, Vol. 114, no. 5, pp. 713-719.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Hensel J.A., Chanda D., Kumar S., Sawant A., Grizzle W.E., Siegal G.P., Ponnazhagan S. LL-37 as a therapeutic target for late stage prostate cancer. Prostate, 2011, Vol. 71, no. 6, pp. 659-670.</mixed-citation><mixed-citation xml:lang="en">Hensel J.A., Chanda D., Kumar S., Sawant A., Grizzle W.E., Siegal G.P., Ponnazhagan S. LL-37 as a therapeutic target for late stage prostate cancer. Prostate, 2011, Vol. 71, no. 6, pp. 659-670.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Henzler-Wildman K.A., Lee D.K., Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry, 2003, Vol. 42, no. 21, pp. 6545-6558.</mixed-citation><mixed-citation xml:lang="en">Henzler-Wildman K.A., Lee D.K., Ramamoorthy A. Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry, 2003, Vol. 42, no. 21, pp. 6545-6558.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Hoskin D.W., Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta, 2008, Vol. 1778, no. 2, pp. 357-375.</mixed-citation><mixed-citation xml:lang="en">Hoskin D.W., Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta, 2008, Vol. 1778, no. 2, pp. 357-375.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">International agency for research of cancer (Globocan ) [Electronic resource]: the World of Health Organization, 2018. Mode of access: http: www.globocan.iarc.fr. Data of access: 23.05.2020.</mixed-citation><mixed-citation xml:lang="en">International agency for research of cancer (Globocan ) [Electronic resource]: the World of Health Organization, 2018. Mode of access: http: www.globocan.iarc.fr. Data of access: 23.05.2020.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell Mol Med., 2011, Vol. 15, no. 5, pp. 1013-1031.</mixed-citation><mixed-citation xml:lang="en">Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell Mol Med., 2011, Vol. 15, no. 5, pp. 1013-1031.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Ishitsuka Y., Pham D.S., Waring A.J., Lehrer R.I., Lee K.Y. Insertion selectivity of antimicrobial peptide protegrin-1 into lipid monolayers: effect of head group electrostatics and tail group packing. Biochim. Biophys. Acta, 2006, Vol. 1758, no. 9, pp. 1450-1460.</mixed-citation><mixed-citation xml:lang="en">Ishitsuka Y., Pham D.S., Waring A.J., Lehrer R.I., Lee K.Y. Insertion selectivity of antimicrobial peptide protegrin-1 into lipid monolayers: effect of head group electrostatics and tail group packing. Biochim. Biophys. Acta, 2006, Vol. 1758, no. 9, pp. 1450-1460.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Jana J., Kar R.K., Ghosh A., Biswas A., Ghosh S., Bhunia A., Chatterjee S. Human cathelicidin peptide LL37 binds telomeric G-quadruplex. Mol. BioSyst., 2013, Vol. 9, pp. 1833-1836.</mixed-citation><mixed-citation xml:lang="en">Jana J., Kar R.K., Ghosh A., Biswas A., Ghosh S., Bhunia A., Chatterjee S. Human cathelicidin peptide LL37 binds telomeric G-quadruplex. Mol. BioSyst., 2013, Vol. 9, pp. 1833-1836.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Ji P., Zhou Y., Yang Y., Wu J., Zhou H., Quan W., Sun J., Yao Y., Shang A., Gu C., Zeng B,, Firrman J., Xiao W., Bals R., Sun Z., Li D. Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling. Theranostics, 2019, Vol. 9, no. 8, pp. 2209-2223.</mixed-citation><mixed-citation xml:lang="en">Ji P., Zhou Y., Yang Y., Wu J., Zhou H., Quan W., Sun J., Yao Y., Shang A., Gu C., Zeng B,, Firrman J., Xiao W., Bals R., Sun Z., Li D. Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/β-catenin signaling. Theranostics, 2019, Vol. 9, no. 8, pp. 2209-2223.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Jia J., Zheng Y., Wang W., Shao Y., Li Z., Wang Q., Wang Y., Yan H. Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells. Mol. Med. Rep., 2017, Vol. 15, no. 1, pp. 240-248.</mixed-citation><mixed-citation xml:lang="en">Jia J., Zheng Y., Wang W., Shao Y., Li Z., Wang Q., Wang Y., Yan H. Antimicrobial peptide LL-37 promotes YB-1 expression, and the viability, migration and invasion of malignant melanoma cells. Mol. Med. Rep., 2017, Vol. 15, no. 1, pp. 240-248.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Johansson J., Gudmundsson G.H., Rottenberg M.E., Berndt K.D., Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol Chem., 1998, Vol. 273, no. 6, pp. 3718-3724.</mixed-citation><mixed-citation xml:lang="en">Johansson J., Gudmundsson G.H., Rottenberg M.E., Berndt K.D., Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol Chem., 1998, Vol. 273, no. 6, pp. 3718-3724.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 2000, Vol. 21, no. 3, pp. 215-244.</mixed-citation><mixed-citation xml:lang="en">Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev., 2000, Vol. 21, no. 3, pp. 215-244.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Kim H.J., Hwang S.W., Kim N., Yoon H., Shin C.M., Park Y.S., Lee D.H., Park D.J., Kim H.H., Kim J.S, Jung H.C, Lee H.S. Helicobacter pylori and molecular markers as prognostic indicators for gastric cancer in Korea. J. Cancer Prev., 2014, Vol. 19, no. 1, pp. 56-67.</mixed-citation><mixed-citation xml:lang="en">Kim H.J., Hwang S.W., Kim N., Yoon H., Shin C.M., Park Y.S., Lee D.H., Park D.J., Kim H.H., Kim J.S, Jung H.C, Lee H.S. Helicobacter pylori and molecular markers as prognostic indicators for gastric cancer in Korea. J. Cancer Prev., 2014, Vol. 19, no. 1, pp. 56-67.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J.E., Kim H.J., Choi J.M., Lee K.H., Kim T.Y., Cho B.K., Jung J.Y., Chung K.Y., Cho D., Park H.J. The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br. J. Dermatol., 2010, Vol. 163, no. 5, pp. 959-967.</mixed-citation><mixed-citation xml:lang="en">Kim J.E., Kim H.J., Choi J.M., Lee K.H., Kim T.Y., Cho B.K., Jung J.Y., Chung K.Y., Cho D., Park H.J. The antimicrobial peptide human cationic antimicrobial protein-18/cathelicidin LL-37 as a putative growth factor for malignant melanoma. Br. J. Dermatol., 2010, Vol. 163, no. 5, pp. 959-967.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Koczulla R., von Degenfeld G., Kupatt C., Krötz F., Zahler S., Gloe T., Issbrücker K., Unterberger P., Zaiou M., Lebherz C., Karl A., Raake P., Pfosser A., Boekstegers P., Welsch U., Hiemstra P.S., Vogelmeier C., Gallo R.L., Clauss M., Bals R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest., 2003, Vol. 111, no. 11, pp. 1665-1672.</mixed-citation><mixed-citation xml:lang="en">Koczulla R., von Degenfeld G., Kupatt C., Krötz F., Zahler S., Gloe T., Issbrücker K., Unterberger P., Zaiou M., Lebherz C., Karl A., Raake P., Pfosser A., Boekstegers P., Welsch U., Hiemstra P.S., Vogelmeier C., Gallo R.L., Clauss M., Bals R. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest., 2003, Vol. 111, no. 11, pp. 1665-1672.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Koensgen D., Bruennert D., Ungureanu S., Sofroni D., Braicu EI., Sehouli J., Sümnig A., Delogu S., Zygmunt M., Goyal P., Evert M., Olek S., Biebler KE., Mustea A. Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine, 2015, Vol. 71, no. 2, pp. 334-338.</mixed-citation><mixed-citation xml:lang="en">Koensgen D., Bruennert D., Ungureanu S., Sofroni D., Braicu EI., Sehouli J., Sümnig A., Delogu S., Zygmunt M., Goyal P., Evert M., Olek S., Biebler KE., Mustea A. Polymorphism of the IL-8 gene and the risk of ovarian cancer. Cytokine, 2015, Vol. 71, no. 2, pp. 334-338.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Kokryakov V.N., Harwig S.S.L., Panyutich E.A., Shevchenko A.A., Aleshina G.M., Shamova O.V., Korneva H.A., Lehrer R.I. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett., 1993, Vol. 327, no. 2, pp. 231-236.</mixed-citation><mixed-citation xml:lang="en">Kokryakov V.N., Harwig S.S.L., Panyutich E.A., Shevchenko A.A., Aleshina G.M., Shamova O.V., Korneva H.A., Lehrer R.I. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett., 1993, Vol. 327, no. 2, pp. 231-236.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Krętowski R., Stypułkowska A., Cechowska-Pasko M. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol. Cell. Biochem., 2015, Vol. 398, no. 1-2, pp. 165-173.</mixed-citation><mixed-citation xml:lang="en">Krętowski R., Stypułkowska A., Cechowska-Pasko M. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol. Cell. Biochem., 2015, Vol. 398, no. 1-2, pp. 165-173.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Kuroda K., Fukuda T., Krstic-Demonacos M., Demonacos C., Okumura K., Isogai H., Hayashi M., Saito K., Isogai E. miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway. BMC Cancer, 2017, Vol. 17, no. 1, 33. doi: 10.1186/s12885-016-3003-9.</mixed-citation><mixed-citation xml:lang="en">Kuroda K., Fukuda T., Krstic-Demonacos M., Demonacos C., Okumura K., Isogai H., Hayashi M., Saito K., Isogai E. miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway. BMC Cancer, 2017, Vol. 17, no. 1, 33. doi: 10.1186/s12885-016-3003-9.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Kuroda K., Fukuda T., Yoneyama H. Katayama M., Isogai H., Okumura K., Isogai E. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53-/-. Oncol. Rep., 2012, Vol. 28, no. 3, pp. 829-834.</mixed-citation><mixed-citation xml:lang="en">Kuroda K., Fukuda T., Yoneyama H. Katayama M., Isogai H., Okumura K., Isogai E. Anti-proliferative effect of an analogue of the LL-37 peptide in the colon cancer derived cell line HCT116 p53+/+ and p53-/-. Oncol. Rep., 2012, Vol. 28, no. 3, pp. 829-834.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Kuroda K., Okumura K., Isogai H., Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol., 2015, Vol. 5, 144. doi: 10.3389/fonc.2015.00144.</mixed-citation><mixed-citation xml:lang="en">Kuroda K., Okumura K., Isogai H., Isogai E. The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front Oncol., 2015, Vol. 5, 144. doi: 10.3389/fonc.2015.00144.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Wang Y.H., Su B., Nestle F.O., Zal T., Mellman I., Schröder J.-M., Liu Y.-J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007, Vol. 449, pp. 564-569.</mixed-citation><mixed-citation xml:lang="en">Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Wang Y.H., Su B., Nestle F.O., Zal T., Mellman I., Schröder J.-M., Liu Y.-J., Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 2007, Vol. 449, pp. 564-569.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Lau Y.E., Rozek A, Scott MG., Goosney D.L., Davidson D.J., Hancock R.EW. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun., 2005, Vol. 73, no. 1, pp. 583-591.</mixed-citation><mixed-citation xml:lang="en">Lau Y.E., Rozek A, Scott MG., Goosney D.L., Davidson D.J., Hancock R.EW. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun., 2005, Vol. 73, no. 1, pp. 583-591.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H.Y., Kim S.D., Shim J.W., Lee S.Y., Yun, J., Bae Y.S. LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils. Exp. Mol. Med., 2009, Vol. 41, pp. 325-333.</mixed-citation><mixed-citation xml:lang="en">Lee H.Y., Kim S.D., Shim J.W., Lee S.Y., Yun, J., Bae Y.S. LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils. Exp. Mol. Med., 2009, Vol. 41, pp. 325-333.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Leifer C.A., Medvedev A.E. Molecular mechanisms of regulation of Toll-like receptor signaling. J. Leukoc. Biol., 2016, Vol. 100, no. 5, pp. 927-941.</mixed-citation><mixed-citation xml:lang="en">Leifer C.A., Medvedev A.E. Molecular mechanisms of regulation of Toll-like receptor signaling. J. Leukoc. Biol., 2016, Vol. 100, no. 5, pp. 927-941.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Li D., Wang X., Wu J.L., Quan W.Q., Ma L., Yang F., Wu K.Y., Wan H.Y. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS One, 2013, Vol. 8, no. 2, e56616. doi: 10.1371/journal.pone.0056616.</mixed-citation><mixed-citation xml:lang="en">Li D., Wang X., Wu J.L., Quan W.Q., Ma L., Yang F., Wu K.Y., Wan H.Y. Tumor-produced versican V1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro. PLoS One, 2013, Vol. 8, no. 2, e56616. doi: 10.1371/journal.pone.0056616.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Lohner K., Blondelle S.E. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen., 2005, Vol. 8, no. 3, pp. 241-256.</mixed-citation><mixed-citation xml:lang="en">Lohner K., Blondelle S.E. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen., 2005, Vol. 8, no. 3, pp. 241-256.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Mader J.S., Mookherjee N., Hancock R.E., Bleackley R.C. The human host defense peptide LL-37 induces apoptosis in a calpain- and apoptosis-inducing factor-dependent manner involving Bax activity. Mol. Cancer Res., 2009, Vol. 7, no. 5, pp. 689-702.</mixed-citation><mixed-citation xml:lang="en">Mader J.S., Mookherjee N., Hancock R.E., Bleackley R.C. The human host defense peptide LL-37 induces apoptosis in a calpain- and apoptosis-inducing factor-dependent manner involving Bax activity. Mol. Cancer Res., 2009, Vol. 7, no. 5, pp. 689-702.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Maga G., Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J. Cell Sci., 2003, Vol. 116, Pt 15, pp. 3051-3060.</mixed-citation><mixed-citation xml:lang="en">Maga G., Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J. Cell Sci., 2003, Vol. 116, Pt 15, pp. 3051-3060.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Mangoni M.E., Aumelas A., Charnet P., Roumestand C., Chiche L., Despaux E., Grassy G., Calas B., Chavanieu A. Change in membrane permeability induced by protegrin 1: implication of disulfide bridges for pore formation. FEBS Lett., 1996, Vol. 383, no. 1-2, pp. 93-98.</mixed-citation><mixed-citation xml:lang="en">Mangoni M.E., Aumelas A., Charnet P., Roumestand C., Chiche L., Despaux E., Grassy G., Calas B., Chavanieu A. Change in membrane permeability induced by protegrin 1: implication of disulfide bridges for pore formation. FEBS Lett., 1996, Vol. 383, no. 1-2, pp. 93-98.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Menssen A., Epanchintsev A., Lodygin D., Rezaei N., Jung P., Verdoodt B., Diebold J., Hermeking H. c-MYC delays prometaphase by direct transactivation of MAD2 and Bub R1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle, 2007, Vol. 6, no. 3, pp. 339-352.</mixed-citation><mixed-citation xml:lang="en">Menssen A., Epanchintsev A., Lodygin D., Rezaei N., Jung P., Verdoodt B., Diebold J., Hermeking H. c-MYC delays prometaphase by direct transactivation of MAD2 and Bub R1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle, 2007, Vol. 6, no. 3, pp. 339-352.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.M., Jemal A., Kramer L., Siegel R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019, Vol. 69, no. 5, pp. 363-385.</mixed-citation><mixed-citation xml:lang="en">Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.M., Jemal A., Kramer L., Siegel R.L. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019, Vol. 69, no. 5, pp. 363-385.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Montreekachon P., Chotjumlong P., Bolscher J.G. Nazmi K., Reutrakul V., Krisanaprakornkit S. Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts. J. Periodontal Res., 2011, Vol. 46, no. 3, pp. 327-337.</mixed-citation><mixed-citation xml:lang="en">Montreekachon P., Chotjumlong P., Bolscher J.G. Nazmi K., Reutrakul V., Krisanaprakornkit S. Involvement of P2X(7) purinergic receptor and MEK1/2 in interleukin-8 up-regulation by LL-37 in human gingival fibroblasts. J. Periodontal Res., 2011, Vol. 46, no. 3, pp. 327-337.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., Powers J.P., Bryan J., Brinkman F.S., Hancock R.E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol., 2006, Vol. 176, no. 4, pp. 2455-2464.</mixed-citation><mixed-citation xml:lang="en">Mookherjee N., Brown K.L., Bowdish D.M., Doria S., Falsafi R., Hokamp K., Roche F.M., Mu R., Doho G.H., Pistolic J., Powers J.P., Bryan J., Brinkman F.S., Hancock R.E. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol., 2006, Vol. 176, no. 4, pp. 2455-2464.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Moon J.Y., Henzler-Wildman K.A., Ramamoorthy A. Expression and purification of a recombinant LL-37 from Escherichia coli. BBA-Biomembranes, 2006, Vol. 1758, no. 9, pp. 1351-1358.</mixed-citation><mixed-citation xml:lang="en">Moon J.Y., Henzler-Wildman K.A., Ramamoorthy A. Expression and purification of a recombinant LL-37 from Escherichia coli. BBA-Biomembranes, 2006, Vol. 1758, no. 9, pp. 1351-1358.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Mostowska A., Sajdak S., Pawlik P., Lianeri M., Jagodzinski P.P. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet. Test. Mol. Biomarkers, 2013, Vol. 17, no. 3, pp. 183-187.</mixed-citation><mixed-citation xml:lang="en">Mostowska A., Sajdak S., Pawlik P., Lianeri M., Jagodzinski P.P. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet. Test. Mol. Biomarkers, 2013, Vol. 17, no. 3, pp. 183-187.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Neto G.T.C., de Lima T.M., Barbeiro H.V., Chammas R.M. Cathelicidin LL-37 Promotes or inhibits cancer cell stemness depending on the tumor origin. Oncomedicine, 2016, Vol. 1, pp. 14-17.</mixed-citation><mixed-citation xml:lang="en">Neto G.T.C., de Lima T.M., Barbeiro H.V., Chammas R.M. Cathelicidin LL-37 Promotes or inhibits cancer cell stemness depending on the tumor origin. Oncomedicine, 2016, Vol. 1, pp. 14-17.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Nilsson M.F., Sandstedt B., Sørensen O., Weber G., Borregaard N., Ståhle-Bäckdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun., 1999, Vol. 67, no. 5, pp. 2561-2566.</mixed-citation><mixed-citation xml:lang="en">Nilsson M.F., Sandstedt B., Sørensen O., Weber G., Borregaard N., Ståhle-Bäckdahl M. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun., 1999, Vol. 67, no. 5, pp. 2561-2566.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Okumura K., Itoh A., Isogai E., Hirose K., Hosokawa Y., Abiko Y., Shibata T., Hirata M., Isogai H. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett., 2004, Vol. 212, no. 2, pp. 185-194.</mixed-citation><mixed-citation xml:lang="en">Okumura K., Itoh A., Isogai E., Hirose K., Hosokawa Y., Abiko Y., Shibata T., Hirata M., Isogai H. C-terminal domain of human CAP18 antimicrobial peptide induces apoptosis in oral squamous cell carcinoma SAS-H1 cells. Cancer Lett., 2004, Vol. 212, no. 2, pp. 185-194.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Oren Z., Lerman J.C., Gudmundsson G.H., Agerberth B., Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-selective activity. Biochem J., 1999, Vol. 341, Pt 3, pp. 501-513.</mixed-citation><mixed-citation xml:lang="en">Oren Z., Lerman J.C., Gudmundsson G.H., Agerberth B., Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-selective activity. Biochem J., 1999, Vol. 341, Pt 3, pp. 501-513.</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Peng L.S., Zhuang Y., Li W.H. Zhou Y-Y., Wang T-T., Chen N., Cheng P., Li B-S., Guo H., Yang S-M., Chen W-S., Zou Q-M. Elevated interleukin-32 expression is associated with Helicobacter pylori-related gastritis. PLoS One, 2014, Vol. 9, no. 3, e88270. doi: 10.1371/journal.pone.0088270.</mixed-citation><mixed-citation xml:lang="en">Peng L.S., Zhuang Y., Li W.H. Zhou Y-Y., Wang T-T., Chen N., Cheng P., Li B-S., Guo H., Yang S-M., Chen W-S., Zou Q-M. Elevated interleukin-32 expression is associated with Helicobacter pylori-related gastritis. PLoS One, 2014, Vol. 9, no. 3, e88270. doi: 10.1371/journal.pone.0088270.</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Piktel E., Niemirowicz K., Wnorowska U., Wątek M., Wollny T., Głuszek K., Góźdź S., Levental I., Bucki R. The role of cathelicidin LL-37 in cancer development. Arch. Immunol. Ther. Exp. (Warsz), 2016, Vol. 64, pp. 33-46.</mixed-citation><mixed-citation xml:lang="en">Piktel E., Niemirowicz K., Wnorowska U., Wątek M., Wollny T., Głuszek K., Góźdź S., Levental I., Bucki R. The role of cathelicidin LL-37 in cancer development. Arch. Immunol. Ther. Exp. (Warsz), 2016, Vol. 64, pp. 33-46.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Prevete N., Liotti F., Visciano C., Marone G., Melillo R.M., de Paulis A. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene, 2015, Vol. 34, no. 29, pp. 3826-3838.</mixed-citation><mixed-citation xml:lang="en">Prevete N., Liotti F., Visciano C., Marone G., Melillo R.M., de Paulis A. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene, 2015, Vol. 34, no. 29, pp. 3826-3838.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Pushpanathan M., Gunasekaran P., Rajendhran J. Antimicrobial peptides: versatile biological properties. Intern. J. Peptides, 2013, Vol. 2013, 675391. doi: 10.1155/2013/675391.</mixed-citation><mixed-citation xml:lang="en">Pushpanathan M., Gunasekaran P., Rajendhran J. Antimicrobial peptides: versatile biological properties. Intern. J. Peptides, 2013, Vol. 2013, 675391. doi: 10.1155/2013/675391.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Qin X., Lu Y., Qin A., Chen Z., Peng Q., Deng Y., Xie L., Wang J., Li R., Zeng J., Li S., Zhao J. Vitamin D receptor BsmІ polymorphism and ovarian cancer risk: a meta-analysis. Int. J. Gynecol. Cancer, 2013, Vol. 23, no. 7, pp. 1178-1183.</mixed-citation><mixed-citation xml:lang="en">Qin X., Lu Y., Qin A., Chen Z., Peng Q., Deng Y., Xie L., Wang J., Li R., Zeng J., Li S., Zhao J. Vitamin D receptor BsmІ polymorphism and ovarian cancer risk: a meta-analysis. Int. J. Gynecol. Cancer, 2013, Vol. 23, no. 7, pp. 1178-1183.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Qiu Y., Li W.H., Zhang H.Q., Liu Y., Tian X.X., Fang W.G. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One, 2014, Vol. 9, no. 12, e114371. doi: 10.1371/journal.pone.0114371.</mixed-citation><mixed-citation xml:lang="en">Qiu Y., Li W.H., Zhang H.Q., Liu Y., Tian X.X., Fang W.G. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One, 2014, Vol. 9, no. 12, e114371. doi: 10.1371/journal.pone.0114371.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Ren S.X., Cheng A.S., To K.F., Tong J.H., Li M.S., Shen J., Wong C.C., Zhang L., Chan R.L., Wang X.J., Ng S.S., Chiu L.C., Marquez V.E., Gallo R.L., Chan F.K., Yu J., Sung J.J., Wu W.K., Cho C.H. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res., 2012, Vol. 72, no. 24, pp. 6512-6523.</mixed-citation><mixed-citation xml:lang="en">Ren S.X., Cheng A.S., To K.F., Tong J.H., Li M.S., Shen J., Wong C.C., Zhang L., Chan R.L., Wang X.J., Ng S.S., Chiu L.C., Marquez V.E., Gallo R.L., Chan F.K., Yu J., Sung J.J., Wu W.K., Cho C.H. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res., 2012, Vol. 72, no. 24, pp. 6512-6523.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Ren S.X., Shen J., Cheng A.S., Lu L., Chan R.L., Li Z.J., Wang X.J., Wong C.C., Zhang L., Ng S.S., Chan F.L., Chan F.K., Yu J., Sung J.J., Wu W.K., Cho C.H. FK-16 derived from the anticancer peptide LL-37 induces caspaseindependent apoptosis and autophagic cell death in colon cancer cells. PLoS One, 2013, Vol. 8, no. 5, e63641. doi: 10.1371/journal.pone.0063641.</mixed-citation><mixed-citation xml:lang="en">Ren S.X., Shen J., Cheng A.S., Lu L., Chan R.L., Li Z.J., Wang X.J., Wong C.C., Zhang L., Ng S.S., Chan F.L., Chan F.K., Yu J., Sung J.J., Wu W.K., Cho C.H. FK-16 derived from the anticancer peptide LL-37 induces caspaseindependent apoptosis and autophagic cell death in colon cancer cells. PLoS One, 2013, Vol. 8, no. 5, e63641. doi: 10.1371/journal.pone.0063641.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, Vol. 414, no. 6859, pp. 105-111.</mixed-citation><mixed-citation xml:lang="en">Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature, 2001, Vol. 414, no. 6859, pp. 105-111.</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Rothan H.A., Mohamed Z., Sasikumar P.G., Reddy K.A., Rahman N.A., Yusof. R. In Vitro Characterization of Novel Protegrin-1 Analogues Against Neoplastic Cells. Intern. J. Peptide Res. Ther, 2014, Vol. 20, no. 3, pp. 259-267.</mixed-citation><mixed-citation xml:lang="en">Rothan H.A., Mohamed Z., Sasikumar P.G., Reddy K.A., Rahman N.A., Yusof. R. In Vitro Characterization of Novel Protegrin-1 Analogues Against Neoplastic Cells. Intern. J. Peptide Res. Ther, 2014, Vol. 20, no. 3, pp. 259-267.</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Sainz B.Jr., Alcala S., Garcia E., Sanchez-Ripoll Y., Azevedo M.M., Cioffi M., Tatari M., Miranda Lorenzo I., Hidalgo M., Gomez-Lopez G., Cañamero M., Erkan M., Kleeff J., García-Silva S., Sancho P., Hermann PC., Heeschen C. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut, 2015, Vol. 64, no. 12, pp. 1921-1935.</mixed-citation><mixed-citation xml:lang="en">Sainz B.Jr., Alcala S., Garcia E., Sanchez-Ripoll Y., Azevedo M.M., Cioffi M., Tatari M., Miranda Lorenzo I., Hidalgo M., Gomez-Lopez G., Cañamero M., Erkan M., Kleeff J., García-Silva S., Sancho P., Hermann PC., Heeschen C. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut, 2015, Vol. 64, no. 12, pp. 1921-1935.</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol., 2009, Vol. 625, no. 1-3, pp. 190-194.</mixed-citation><mixed-citation xml:lang="en">Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol., 2009, Vol. 625, no. 1-3, pp. 190-194.</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Shaykhiev R., Beisswenger C., Kändler K., Senske J., Püchner A., Damm T., Behr J., Bals R. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol., 2005, Vol. 289, pp. L842-L848.</mixed-citation><mixed-citation xml:lang="en">Shaykhiev R., Beisswenger C., Kändler K., Senske J., Püchner A., Damm T., Behr J., Bals R. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell. Mol. Physiol., 2005, Vol. 289, pp. L842-L848.</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Simons K., Ikonen E. How cells handle cholesterol. Science, 2000, Vol. 290, no. 5497, pp. 1721-1726.</mixed-citation><mixed-citation xml:lang="en">Simons K., Ikonen E. How cells handle cholesterol. Science, 2000, Vol. 290, no. 5497, pp. 1721-1726.</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Sørensen O., Arnljots K., Cowland J.B., Bainton D.F., Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood, 1997, Vol. 90, no. 7, pp. 2796-2803.</mixed-citation><mixed-citation xml:lang="en">Sørensen O., Arnljots K., Cowland J.B., Bainton D.F., Borregaard N. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood, 1997, Vol. 90, no. 7, pp. 2796-2803.</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Sørensen O.E., Gram L., Johnsen A.H., Andersson E., Bangsbøll S., Tjabringa G.S., Hiemstra P.S., Malm J., Egesten A., Borregaard N. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem., 2003, Vol. 278, no. 31, pp. 28540-28546.</mixed-citation><mixed-citation xml:lang="en">Sørensen O.E., Gram L., Johnsen A.H., Andersson E., Bangsbøll S., Tjabringa G.S., Hiemstra P.S., Malm J., Egesten A., Borregaard N. Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J. Biol. Chem., 2003, Vol. 278, no. 31, pp. 28540-28546.</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Sorrentino C., di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J. Respir. Crit. Care Med., 2009, Vol. 180, no. 8, pp. 769-779.</mixed-citation><mixed-citation xml:lang="en">Sorrentino C., di Carlo E. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J. Respir. Crit. Care Med., 2009, Vol. 180, no. 8, pp. 769-779.</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Soundrarajan N., Park S., Quy L.V.C., Cho H-S., Raghunathan G., Ahn B., Song H., Kim J-H., Park C. Protegrin-1 cytotoxicity towards mammalian cells positively correlates with the magnitude of conformational changes of the unfolded form upon cell interaction. Sci. Rep., 2019, Vol. 9, 11569. doi: 10.1038/s41598-019-47955-2.</mixed-citation><mixed-citation xml:lang="en">Soundrarajan N., Park S., Quy L.V.C., Cho H-S., Raghunathan G., Ahn B., Song H., Kim J-H., Park C. Protegrin-1 cytotoxicity towards mammalian cells positively correlates with the magnitude of conformational changes of the unfolded form upon cell interaction. Sci. Rep., 2019, Vol. 9, 11569. doi: 10.1038/s41598-019-47955-2.</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Sugawara K., Shinohara H., Kadoya T., Kuramitz H. Sensing lymphoma cells based on a cell-penetrating/ apoptosis-inducing/electron-transfer peptide probe. Anal. Chim. Acta, 2016, Vol. 924, pp. 106-113.</mixed-citation><mixed-citation xml:lang="en">Sugawara K., Shinohara H., Kadoya T., Kuramitz H. Sensing lymphoma cells based on a cell-penetrating/ apoptosis-inducing/electron-transfer peptide probe. Anal. Chim. Acta, 2016, Vol. 924, pp. 106-113.</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Sun J. The Role of Vitamin D and Vitamin D receptors in colon cancer. Clin. Transl. Gastroenterol., 2017, Vol. 8, no. 6, e103. doi: 10.1038/ctg.2017.31.</mixed-citation><mixed-citation xml:lang="en">Sun J. The Role of Vitamin D and Vitamin D receptors in colon cancer. Clin. Transl. Gastroenterol., 2017, Vol. 8, no. 6, e103. doi: 10.1038/ctg.2017.31.</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki K., Murakami T., Hu Z., Tamura H., Kuwahara-Arai K., Iba T., Nagaoka I. Human host defense cathelicidin peptide ll-37 enhances the lipopolysaccharide uptake by liver sinusoidal endothelial cells without cell activation. J. Immunol., 2016, Vol. 196, no. 3, pp. 1338-1347.</mixed-citation><mixed-citation xml:lang="en">Suzuki K., Murakami T., Hu Z., Tamura H., Kuwahara-Arai K., Iba T., Nagaoka I. Human host defense cathelicidin peptide ll-37 enhances the lipopolysaccharide uptake by liver sinusoidal endothelial cells without cell activation. J. Immunol., 2016, Vol. 196, no. 3, pp. 1338-1347.</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Takazawa Y., Kiniwa Y., Ogawa E., Uchiyama A., Ashida A., Uhara H., Goto Y., Okuyama R. Toll-like receptor 4 signaling promotes the migration of human melanoma cells. Tohoku J. Exp. Med., 2014, Vol. 234, no. 1, pp. 57-65.</mixed-citation><mixed-citation xml:lang="en">Takazawa Y., Kiniwa Y., Ogawa E., Uchiyama A., Ashida A., Uhara H., Goto Y., Okuyama R. Toll-like receptor 4 signaling promotes the migration of human melanoma cells. Tohoku J. Exp. Med., 2014, Vol. 234, no. 1, pp. 57-65.</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Tjabringa G.S., Ninaber D.K., Drijfhout J.W., Rabe K.F., Hiemstra P.S. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol., 2006, Vol. 140, no. 2, pp. 103-112.</mixed-citation><mixed-citation xml:lang="en">Tjabringa G.S., Ninaber D.K., Drijfhout J.W., Rabe K.F., Hiemstra P.S. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol., 2006, Vol. 140, no. 2, pp. 103-112.</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Tokumaru S., Sayama K., Shirakata Y., Komatsuzawa H., Ouhara K., Hanakawa Y., Yahata Y., Dai X., Tohyama M., Nagai H., Yang L., Higashiyama S., Yoshimura A., Sugai M., Hashimoto K. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol., 2005, Vol. 175, no. 7, pp. 4662-4668.</mixed-citation><mixed-citation xml:lang="en">Tokumaru S., Sayama K., Shirakata Y., Komatsuzawa H., Ouhara K., Hanakawa Y., Yahata Y., Dai X., Tohyama M., Nagai H., Yang L., Higashiyama S., Yoshimura A., Sugai M., Hashimoto K. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol., 2005, Vol. 175, no. 7, pp. 4662-4668.</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Vandamme D., Landuyt B., Luyten W., Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol., 2012, Vol. 280, no. 1, pp. 22-35.</mixed-citation><mixed-citation xml:lang="en">Vandamme D., Landuyt B., Luyten W., Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol., 2012, Vol. 280, no. 1, pp. 22-35.</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Vignoni M., de Alwis Weerasekera H., Simpson M.J. Phopase J., Mah T-F., Griffith M., Alarcon E.I., Scaiano J.C. LL37 peptide@silver nanoparticles: combining the best of the two worlds for skin infection control. Nanoscale, 2014, Vol. 6, no. 11, pp. 5725-5728.</mixed-citation><mixed-citation xml:lang="en">Vignoni M., de Alwis Weerasekera H., Simpson M.J. Phopase J., Mah T-F., Griffith M., Alarcon E.I., Scaiano J.C. LL37 peptide@silver nanoparticles: combining the best of the two worlds for skin infection control. Nanoscale, 2014, Vol. 6, no. 11, pp. 5725-5728.</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">von Haussen J., Koczulla R., Shaykhiev R., Herr C., Pinkenburg O., Reimer D., Wiewrodt R., Biesterfeld S., Aigner A., Czubayko F., Bals R. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer, 2008, Vol. 59, no. 1, pp. 12-23.</mixed-citation><mixed-citation xml:lang="en">von Haussen J., Koczulla R., Shaykhiev R., Herr C., Pinkenburg O., Reimer D., Wiewrodt R., Biesterfeld S., Aigner A., Czubayko F., Bals R. The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer, 2008, Vol. 59, no. 1, pp. 12-23.</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Dong C., Li X., Han W., Su X. Anticancer potential of bioactive peptides from animal sources. Oncol. Rep., 2017, Vol. 38, no. 2, pp. 637-651.</mixed-citation><mixed-citation xml:lang="en">Wang L., Dong C., Li X., Han W., Su X. Anticancer potential of bioactive peptides from animal sources. Oncol. Rep., 2017, Vol. 38, no. 2, pp. 637-651.</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Zheng Y., Jia J., Li C., Duan Q., Li R., Wang X., Shao Y., Chen C., Yan H. Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. Exp. Ther. Med., 2017, Vol. 14, no. 1, pp. 499-506.</mixed-citation><mixed-citation xml:lang="en">Wang W., Zheng Y., Jia J., Li C., Duan Q., Li R., Wang X., Shao Y., Chen C., Yan H. Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1. Exp. Ther. Med., 2017, Vol. 14, no. 1, pp. 499-506.</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Wang W., Jia J., Li C., Duan Q., Yang J., Wang X., Li R., Chen C., Yan H., Zheng Y. Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. Oncol. Lett., 2016, Vol. 12, no. 3, pp. 1745-1752.</mixed-citation><mixed-citation xml:lang="en">Wang W., Jia J., Li C., Duan Q., Yang J., Wang X., Li R., Chen C., Yan H., Zheng Y. Antimicrobial peptide LL-37 promotes the proliferation and invasion of skin squamous cell carcinoma by upregulating DNA-binding protein A. Oncol. Lett., 2016, Vol. 12, no. 3, pp. 1745-1752.</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Weber G., Chamorro C.I., Granath F., Liljegren A., Zreika S., Saidak Z., Sandstedt B., Rotstein S., Mentaverri R., Sánchez F., Pivarcsi A., Ståhle M. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res., 2009, Vol. 11, R6. doi: 10.1186/bcr2221.</mixed-citation><mixed-citation xml:lang="en">Weber G., Chamorro C.I., Granath F., Liljegren A., Zreika S., Saidak Z., Sandstedt B., Rotstein S., Mentaverri R., Sánchez F., Pivarcsi A., Ståhle M. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res., 2009, Vol. 11, R6. doi: 10.1186/bcr2221.</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Wu W.K., Cho C.H., Lee C.W., Wu K., Fan D., Yu J., Sung J.J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett., 2010, Vol. 293, no. 1, pp. 15-22.</mixed-citation><mixed-citation xml:lang="en">Wu W.K., Cho C.H., Lee C.W., Wu K., Fan D., Yu J., Sung J.J. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett., 2010, Vol. 293, no. 1, pp. 15-22.</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Wu W.K., Sung J.J., To K.F., Yu L., Li H.T., Li Z.J., Chu K.M., Yu J., Cho C.H. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J. Cell. Physiol., 2010, Vol. 223, pp. 178-186.</mixed-citation><mixed-citation xml:lang="en">Wu W.K., Sung J.J., To K.F., Yu L., Li H.T., Li Z.J., Chu K.M., Yu J., Cho C.H. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J. Cell. Physiol., 2010, Vol. 223, pp. 178-186.</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Yan H.X., Wu H.P., Zhang H.L., Ashton C., Tong C., Wu J., Qian Q.J., Wang H.Y., Ying Q.L. DNA damageinduced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats. Oncogene, 2013, Vol. 32, no. 38, pp. 4565-4571.</mixed-citation><mixed-citation xml:lang="en">Yan H.X., Wu H.P., Zhang H.L., Ashton C., Tong C., Wu J., Qian Q.J., Wang H.Y., Ying Q.L. DNA damageinduced sustained p53 activation contributes to inflammation-associated hepatocarcinogenesis in rats. Oncogene, 2013, Vol. 32, no. 38, pp. 4565-4571.</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Yang D., Chertov O., Oppenheim J.J. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukoc. Biol., 2001, Vol. 69, no. 5, pp. 691-697.</mixed-citation><mixed-citation xml:lang="en">Yang D., Chertov O., Oppenheim J.J. Participation of mammalian defensins and cathelicidins in antimicrobial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukoc. Biol., 2001, Vol. 69, no. 5, pp. 691-697.</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Yang De, Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J., Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp Med., 2000, Vol. 192, no. 7, pp. 1069-1074.</mixed-citation><mixed-citation xml:lang="en">Yang De, Chen Q., Schmidt A.P., Anderson G.M., Wang J.M., Wooters J., Oppenheim J.J., Chertov O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp Med., 2000, Vol. 192, no. 7, pp. 1069-1074.</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng Q., Li S., Zhou Y., Ou W., Cai X., Zhang L., Huang W., Huang L., Wang Q. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine, 2014, Vol. 65, no. 1, pp. 24-32.</mixed-citation><mixed-citation xml:lang="en">Zeng Q., Li S., Zhou Y., Ou W., Cai X., Zhang L., Huang W., Huang L., Wang Q. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine, 2014, Vol. 65, no. 1, pp. 24-32.</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao X., Wu H., Lu H., Li G., Huang Q. LAMP: a database linking antimicrobial peptides. PLoS One, 2013, Vol. 8, no. 6, e66557. doi: 10.1371/journal.pone.0066557.</mixed-citation><mixed-citation xml:lang="en">Zhao X., Wu H., Lu H., Li G., Huang Q. LAMP: a database linking antimicrobial peptides. PLoS One, 2013, Vol. 8, no. 6, e66557. doi: 10.1371/journal.pone.0066557.</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Zharkova M.S., Orlov D.S., Golubeva O.Y., Chakchir O.B., Eliseev I.E., Grinchuk T.M., Shamova O.V. Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics-a novel way to combat antibiotic resistance? Front. Cell. Infect. Microbiol., 2019, Vol. 9, 128. doi: 10.3389/fcimb.2019.00128.</mixed-citation><mixed-citation xml:lang="en">Zharkova M.S., Orlov D.S., Golubeva O.Y., Chakchir O.B., Eliseev I.E., Grinchuk T.M., Shamova O.V. Application of antimicrobial peptides of the innate immune system in combination with conventional antibiotics-a novel way to combat antibiotic resistance? Front. Cell. Infect. Microbiol., 2019, Vol. 9, 128. doi: 10.3389/fcimb.2019.00128.</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y., Wang P.P., Zhai G., Bapat B., Savas S., Woodrow J.R., Sharma I., Li Y., Zhou X., Yang N., Campbell P.T., Dicks E., Parfrey P.S., Mclaughlin J.R. Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population. Br. J. Cancer, 2017, Vol. 117, no. 6, pp. 898-906.</mixed-citation><mixed-citation xml:lang="en">Zhu Y., Wang P.P., Zhai G., Bapat B., Savas S., Woodrow J.R., Sharma I., Li Y., Zhou X., Yang N., Campbell P.T., Dicks E., Parfrey P.S., Mclaughlin J.R. Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population. Br. J. Cancer, 2017, Vol. 117, no. 6, pp. 898-906.</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Zwaal R.F., Comfurius P., Bevers E.M. Surface exposure of phosphatidylserine in pathological cells. Cell. Mol. Life Sci., 2005, Vol. 62, no. 9, pp. 971-988.</mixed-citation><mixed-citation xml:lang="en">Zwaal R.F., Comfurius P., Bevers E.M. Surface exposure of phosphatidylserine in pathological cells. Cell. Mol. Life Sci., 2005, Vol. 62, no. 9, pp. 971-988.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
